anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This observational study is investigating a simple test of usual walking speed, measured using the 4 metre gait speed (4MGS) test in patients with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). Drug development for this disease is slow in part because there is a lack of reliable measurements that can assess the effectiveness of treatment. Death and hospital admissions are currently considered meaningful endpoints in research trials due to the lack of fully validated surrogate endpoints in IPF. Using surrogate endpoints could reduce the sample size, cost and duration of clinical trials in IPF perhaps permitting more rapid drug development. Slow walking speed has been shown to be consistently associated with survival and a risk factor for disability, institutionalisation and hospitalisation in older adults and people with another lung disease called Chronic Obstructive Pulmonary Disease (COPD). We are interested to see whether usual walking speed and change in usual walking speed over 6 months predicts death and hospital admissions in IPF patients. This will help inform us of the potential use of 4MGS as a surrogate endpoint. To do this, participants who consent to taking part in the study will be timed walking at their usual walking speed over a distance of 4 metres (13.12 feet) at one time point and then six months later. Incidence of mortality and non-elective hospital admissions will be assessed at 12 months.
Patients will be ventilated in volume-controlled mode with Vt at 6 ml/kg of predicted body weight. Prone positioning will be performed over periods of 16 hours when PaO2/FiO2 was persistently lower than 150 mm Hg. Flow, volume, and airway pressure will bw measured by ventilators. Measurements of oxygenation and respiratory mechanics were performed at 5 and 15 cmH20 PEEP levels and will be repeated every season as before first period of prone positioning, before supine positioning, and again before second period of prone positioning. Total PEEP and plateau pressure will be measured by a short end-expiratory and an end-inspiratory occlusion respectively. Complete airway closure will be assessed by performing a low-flow (4 L/min) inflation( PV tool) (9). The potential for lung recruitment will be assessed by means of the R/I ratio (10).
7-Methylxanthine (7-MX, CAS No. 552-62-5, purity 99.46%) is the first orally administered drug candidate, which showed anti-myopic activity in different pre-clinical studies. In the present study, we investigated the in-vivo genotoxic and mutagenic toxicity of 7-MX in Wistar rats using comet/single-cell gel electrophoresis, chromosomal aberration and micronucleus assays after oral administration. For the single-dose study (72 h), two doses of 7-MX 300 and 2000 mg/kg body weight were selected. For a repeated dose 28 d study, three doses (250, 500, and 1000 mg/kg) of 7-MX were selected. The doses were administered via oral gavage in the suspension form. Blood and major vital organs such as bone marrow, lung and liver were used to perform comet/single cell gel electrophoresis, chromosomal aberration, and micronucleus assays. The in-vitro Ames test was performed on TA98 and TA100 strains. In the chromosomal aberration study, a non-significant increase in deformities such as stickiness, ring chromosome, and endoreduplication was observed in bone marrow cells of 7-MX treated groups. These chromosomal alterations were observed upon treatment with doses of 2000 mg/kg single dose for 72 h and 1000 mg/kg repeated dose for 28 d. At a dose of 500 mg/kg, DNA damage in terms of tail length, tail moment, % tail DNA and the olive tail moment was also found to be non-significant in 7-MX treated groups. The Ames test showed the non-mutagenic nature of 7-MX in both strains of TA98 and TA100 of Salmonella typhimurium with or without metabolic activation. Thus, the present work is interesting in view of the non- genotoxicity and non-mutagenicity of repeated doses of 7-MX.
To explore the clinical characteristics of patients infected with SARS-CoV-2 nationwide, especially the effect factors of asymptomatic infection and disappearance of clinical symptoms. A total of 66,448 COVID-19 patients in China who have been diagnosed by nucleic acid test or rapid antigen test were surveyed online (December 24, 2022 to January 16, 2023). Our cross-sectional study used descriptive analyses and binary Logistics regression model to assess the correlation between the clinical characteristics and relative factors, including age, gender, pre-existing conditions, reinfection, vaccination and treatment. A total of 64,515 valid questionnaires were collected. Among included participants, 5969 of which were asymptomatic. The symptoms were mainly upper respiratory symptoms, including dry and itchy throat (64.16%), sore throat (59.95%), hoarseness (57.90%), nasal congestion (53.39%). In binary Logistics regression model, we found that male, no pre-existing conditions, reinfection and vaccination have positive correlations with the appearance of asymptomatic COVID-19 patients. In Cox proportional-hazards regression model, considering all clinical symptoms disappeared in 14 days as outcome, we found that ≤ 60 years old, male, no pre-existing conditions, vaccination and adopted treatment have positive correlations with rapid amelioration of clinical symptoms in COVID-19 patients. The clinical symptoms of the participants were mainly upper respiratory symptoms which were according with the infection of Omicron variant. Factors including age, gender, pre-existing conditions and reinfection could influence the clinical characteristics and prognosis of COVID-19 patients. Importantly, vaccination has positive significance for the prevention and treatment of COVID-19. Lastly, the use of Chinese medicine maybe beneficial to COVID-19 patients, however, reasonable guidance is necessary.
PURPOSE:To provide the subject pigment which has not only improved extensibility on and adhesion to the skin but also light-scattering capability. CONSTITUTION:Ultrafine barium sulfate particles having a mean particle diameter of 0.1mum or lower are deposited on the surfaces of fine flaky particles of a pigment substrate by using an aq. soln. of a complex-forming agent capable of forming a complex compd. with a barium ion, an aq. soln. of a water--sol. barium compd., and an aq. soln. contg. sulfate ions, thus giving the objective pigment. This pigment is used for coloring pigments for cosmetics, automotive topcoating, plastic, printing ink, electrical home appliance, paint, and building paint.
This was a prospective exploratory pilot study with a dietary intervention. Twenty-three (23) women volunteered and participated in this study. The eligibility (no menstrual period for at least 12 months) of the participants was determined using a questionnaire. The participants were postmenopausal women between the ages of 50-75 years old who met the exclusion criteria including no recent antibiotics or immunosuppressive therapies, surgery of the stomach, small or large intestines, appendectomy, gastric bypass or gastric banding in the previous 6 months, and diagnostic with any autoimmune diseases.

This study was a randomized, placebo-controlled, crossover, pilot dietary intervention. Ocean Spray Cranberries, Inc provided the experimental and placebo beverages, which have been validated and used in previous studies \[26-29\]. Both beverages were similar in appearance, taste, and aroma and assigned to volunteers according to computer-generated random orders. Both investigators and participants were blind to the assignment and products are identified by a random 3-digit code pre-printed on the cap. The participants consumed either cranberry juice or placebo beverage daily (8 fl oz per day) for 15 days
The routine data of all statutorily insured persons according to the Data Transparency Regulation (DaTraV data) represent a promising data source for the recurrent and timely surveillance of non-communicable diseases (NCDs) in Germany. Thereby, it has become apparent that there is a high demand for reference evaluations that enable quick and regularly repeatable analyses on important NCDs. Against this background, ReFern-01 was initiated, a joint project of the Robert Koch Institute (RKI) and the Federal Institute for Drugs and Medical Devices (BfArM). In collaboration with experts from the field of secondary data analysis and healthcare research, reference evaluations for estimating prevalence, incidence, and mortality for important public health-relevant diseases were developed. First, 11 central NCDs were selected by means of an online survey, and initial case definitions were created in conjunction with a literature review. These were then discussed and agreed upon in a virtual workshop. The created reference evaluations (analysis scripts) allow a standardized estimation of the mentioned epidemiological figures, which are comparable over time and regionally. In addition to providing the results, the scripts will be available at the BfArM for further analysis. Provided that remote access to the analysis of the DaTraV data is available in the future, the results of the ReFern project can strengthen the surveillance of NCDs and support public health actors, for example, in the planning and implementation of health promotion and prevention measures at the federal, state, county, and local levels.
The invention relates to a traditional Chinese medicine composition for treating mink viral enteritis. The traditional Chinese medicine composition is prepared from rhizoma zingiberis, scutellaria baicalensis, coptis chinensis, the root of kudzu vine, ginseng, the root of Chinese pulsatilla, hairyvein agrimony, patrinia, bletilla, panax notoginseng and liquorice. The traditional Chinese medicine composition can be powder. The preparation method comprises the following steps: (1) selecting, namely selecting impurities, stones and metals, and removing the non-medicinal part; (2) washing, namely allowing water in an amount of 2-3 times to slowly enter by using an infiltration method, so that the drug is penetrated into the water; (3) drying, namely drying under reduced pressure at the temperature of 40-60 DEG C until the material is completely dried; (4) grinding, namely respectively performing superfine grinding on each component, and allowing the component to pass through a 600-mesh sieve; (5) mixing, namely weighing according to the weight, and mixing to be uniform within 10-20 minutes; and (6) packaging into bags, wherein the weight of each bag is 100-200g, thereby obtaining the finished product. The formula has the effects of invigorating splenic yang and checking diarrhea, strengthening yin and stopping dysentery, removing stasis and stopping bleeding and reducing swelling and relieving pain. Moreover, the traditional Chinese medicine does not have drug residues, is environmentally friendly, safe and reliable and is one of the main development directions of medicines for preventing and treating mink farming diseases in the future.
Each dose is 10 intranasal insufflations totaling 1.0 mL of a solution containing all ingredients in Syntocinon Spray except oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
The present invention relates to a pill preparation for treating hepatitis A, hepatitis B and chronic hepatitis, which is prepared from the following raw materials by weight: 1 portion of heterophylly falsesatarwort root, 1 portion of Liao schisandra chinensis, 2 portions of Sichuan rhubarb, 1 portion of paris root, 1 portion of white peony alba, 0.75 portion of alum, 1 portion of curcuma root and 2 portions of malan flower. More than one kilogram of raw material mixed powder is added to a modulated concentration solution with the concentration of 300 to 500 ml so as to modulate the powder into the pill preparation with 6 to 10 pills per gram, wherein the modulated concentration solution comprises the following raw materials by weight: 2 portions of herba hyperici japonici, 2 portions of giant knotweed rhizome, 2 portions of strngy stonecrop herb, 1 portion of buffalo horn sheet, 1 portion of lightyellow sophora root, 1 portion of ganoderma and 1 portion of virgate wormwood herb. A mixture of more than one kilogram of raw materials is decocted in water, and then the modulated concentration solution with the concentration of 300 to 500 ml is obtained by means of filtering and concentration. The pill preparation prepared from traditional Chinese medicine can obviously improve the symptoms of the digestive tract, such as nausea, anorexia, etc., and can reduce the content of transaminase, and the pill preparation has a certain function of jaundice elimination. Moreover, with the advantages of rapid effect and low price, the pill preparation is suitable for people living in rural areas and people belonging to lower income groups to use. The present invention also provides a method for preparing the pill preparation.
Gut peptides play a role in signaling appetite control in the hypothalamus. Limited knowledge exists regarding the release of these peptides in individuals with obesity before and during external stimuli. We hypothesize that the expression of gut peptides is different in the fasting and postprandial states in the scenario of obesity. PubMed/MEDLINE, Scopus, and Science Direct electronic databases were searched. The meta-analysis was performed using Review Manager Software. Randomized controlled trials that measured gut peptides in both obese and lean subjects were included in the analysis. A total of 552 subjects with obesity were enrolled in 25 trials. The gut peptide profile did not show any significant difference between obese and lean subjects for glucagon-like peptide 1 (95% confidence interval [CI], -1.21 to 0.38; P = .30), peptide YY (95% CI, -1.47 to 0.18; P = .13), and cholecystokinin (95% CI, -1.25 to 1.28; P = .98). Gut peptides are decreased by an increased high-fat, high-carbohydrate diet and by decreased chewing. There is no statistically significant difference in gut peptides between individuals with obesity and leanness in a fasting state. However, the release of gut peptides is affected in individuals with obesity following external stimuli, such as dietary interventions and chewing. Further studies are necessary to investigate the relationship between various stimuli and the release of gut peptides, as well as their impact on appetite regulation in subjects with obesity.
Cardiomyopathy, manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic decreases in ejection fraction, has been reported in patients treated with BRAFTOVI in combination with binimetinib. In COLUMBUS, evidence of cardiomyopathy (decreased in LVEF below the institutional LLN with an absolute decreased in LVEF ≥10% below baseline as detected by echocardiography or MUGA) occurred in 7% of patients receiving BRAFTOVI plus binimetinib. Grade 3 left ventricular dysfunction occurred in 1.6% of patients. The median time to first occurrence of left ventricular dysfunction (any grade) in patients receiving BRAFTOVI in combination with binimetinib was 3.6 months (range 0 to 21 months). Cardiomyopathy resolved in 87% of patients receiving BRAFTOVI plus binimetinib.

In PHAROS, evidence of cardiomyopathy (decrease in LVEF below the institutional LLN with an absolute decrease in LVEF ≥10% below baseline as detected by echocardiography or MUGA) occurred in 11% of patients receiving BRAFTOVI in combination with binimetinib. Grade 3 left ventricular dysfunction occurred in 1% of patients. Cardiomyopathy resolved in 82% of patients receiving BRAFTOVI plus binimetinib. 

Assess ejection fraction by echocardiogram or MUGA scan prior to initiating treatment, one month after initiating treatment, and every 2 to 3 months during treatment. The safety of BRAFTOVI in combination with binimetinib has not been established in patients with baseline ejection fraction that is either below 50% or below the institutional lower limit of normal (LLN). Patients with cardiovascular risk factors should be monitored closely when treated with BRAFTOVI.

Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction [see Dosage and Administration (2.3), Adverse Reactions (6.1)].
The present invention belongs to a preparation method for medicine of treating dental hypersensitiveness diseases, which comprises: 15 to 20 portions of sunflower seed oil, 2 to 4 portions of 75% sodium fluoride, 2 to 4 portions of 50% glycerol and 1 to 2 portions of 75% alcohol are put into a container at a normal temperature, and are uniformly mixed and stirred so as to be made into a viscous pasty state. The sunflower seed oil is used as main medicine and the sodium fluoride, the glycerol and the alcohol are used as auxiliary medicine by the present invention so as to exert pharmacological actions jointly. Desensitizing medicine prepared by the method has the advantages of high local concentration, quick actions and long maintaining effective time. An effective rate reaches above 90%, and a relapse rate is below 10%. A patient can be cured by only one time of doctor visit. The medicine has no side effect and does not corrode or stimulate oral mucosa.
Is fluid responsiveness, what means a better cardiac output, equal to the need for fluid for a better organ perfusion? In hospital the investigators are now looking to the pump function of the heart, as there is not a better measurement. However this gives no information about necessity of giving fluids. A healthy volunteer also gives a better pump function of the heart after fluid, but that fluid is not necessary and gives no better organ perfusion. The question is: How many percent of the patients have a MFI score of \< 2.6, when the doctor on clinical basis plans to give fluid to the patient, improves organ perfusion after fluid, and is this correlated with an improvement of the cardiac output All intensive care patients who need extra fluid are eligible for this study. Before and after the fluid challenge we do SDF imaging sublingual. Per patient the investigators do this 1x in 24 hours. Concurrently, data on both patient characteristics (e.g. severity of illness) will be obtained Study population max 100 patients. Possible outcome: MFI \< 2,6 en SV \> 10% + MFI up MFI \< 2,6 en SV equal + MFI equal MFI \< 2,6 en SV \> 10% + MFI equal MFI \< 2,6 en SV equal + MFI up MFI \> 2,6 en SV \> 10% + MFI up MFI \> 2,6 en SV equal + MFI equal MFI \> 2,6 en SV \> 10% + MFI equal MFI \> 2,6 en SV equal + MFI up
The invented capsule is prepared from deglued antler powder, pillose asiabell root, pangolin scales, edible tulip, rhizoma corydalls, white mastard seed, root of Chinese thorowax, root-tuber of aromatic turmetic, rhizome of nutgras sflatsedge etc. in accordance with a specific compounding ratio. It is made up through the following steps: the raw medicines are partially crushed and sieved, the remainder medicines are decocted, filtered and concentrated. Then two parts are mixed, dry-hot sterilized and finished after filling in capsule. Said product possesses of the functions of reinforcing of the kidney, invigorating the function of the spleen, regulating of Chong and Ren, smooting of the liver, resolving of masses, removing of blood stasis, promoting flow of qi and stopping of pain. Said capsule features convenint for taking, reliable curative effect and being an ideal medicine for treating hyperplasia of mammary gland.
The possibility of ovulation and conception prior to initiation of medication should be considered. The patient should be instructed to begin taking Lutera on either the first Sunday after the onset menstruation (Sunday Start) or on Day 1 of menstruation (Day 1 Start).

### Sunday Start

The patient is instructed to begin taking Lutera on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, the first tablet (white) is taken that day. One white tablet should be taken daily for 21 consecutive days, followed by one peach inert tablet daily for 7 consecutive days. Withdrawal bleeding should usually occur within three days following discontinuation of white tablets and may not have finished before the next pack is started. During the first cycle, contraceptive reliance should not be placed on Lutera until a white tablet has been taken daily for 7 consecutive days, and a nonhormonal back-up method of birth control should be used during those 7 days.

### Day 1 start

During the first cycle of medication, the patient is instructed to begin taking Lutera during the first 24 hours of her period (day one of her menstrual cycle). One white tablet should be taken daily for 21 consecutive days, followed by one peach inert tablet daily for 7 consecutive days. Withdrawal bleeding should usually occur within three days following discontinuation of white tablets and may not have finished before the next pack is started. If medication is begun on day one of the menstrual cycle, no back-up contraception is necessary. If Lutera tablets are started later than day one of the first menstrual cycle or postpartum, contraceptive reliance should not be placed on Lutera tablets until after the first 7 consecutive days of administration, and a nonhormonal back-up method of birth control should be used during those 7 days.
The invention relates to an agent for changing the color of keratinous fibers, in particular human hair. In a cosmetic carrier, such agents contain at least one coloring component and at least one cationizable copolymer that is not permanently ionic. Said copolymer is derived from at least one cationizable monomer of the general formula (F1), where R1 and R2 independently of each other represent hydrogen or a methyl group, R3 and R4 independently of each other represent alkyl groups having 1 to 4 carbon atoms, Y represents an NH group or an oxygen atom, and p represents an integral number between 2 and 5. Said agents can be obtained, in particular, by mixing the individual components of a multiple-component packaging unit, wherein oxidation dye precursor products and direct-dyeing colorants can be used as coloring agents. The invention further relates to a method for applying such agents on keratinous fibers. Moreover, the invention relates to the use of said agent for improving color retention.
The invention discloses a traditional Chinese medicine (TCM) composition and a preparation method and application thereof. The TCM composition comprises the following active ingredients in parts by weight: 5 to 45 parts of trillium tschonoskii, 10 to 90 parts of salvia miltiorrhiza, and 3 to 30 parts of ligusticum wallichii. The preparation method of the TCM composition comprises the following steps of: mixing trillium tschonoskii, salvia miltiorrhiza, and ligusticum wallichii in parts by weight to obtain a mixture; adding water to the mixture for soaking; then decocting for two to three times, filtering, and combining filtrates to obtain the composition. The traditional pharmaceutical trillium tschonoskii of Tujia people has sedation and analgesia functions, salvia miltiorrhiza has efficacies of tranquilizing by nourishing the heart, and relieving restlessness by clearing the heart, and ligusticum wallichii has efficacies of promoting the circulation of qi by activating blood, and promoting the blood circulation of head and eyes. The number of medicines is few, the compatibility is rigorous, and the composition has efficacies of promoting blood circulation to remove meridian obstruction and ataralgesia. The TCM composition play an exact role in clinic treatment of migraine, can ease neurasthenia, restlessness, anxiety and other mental behavior symptoms, reduces migraine attack frequency and intensity, relieves the suffering of patients, and improves the quality of life of the patients.